Crossmark Global Holdings Inc. Takes $2.57 Million Position in Charles River Laboratories International, Inc. (CRL)

Crossmark Global Holdings Inc. acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 23,749 shares of the medical research company’s stock, valued at approximately $2,565,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Charles River Laboratories International by 12.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 202 shares in the last quarter. Riverhead Capital Management LLC boosted its stake in shares of Charles River Laboratories International by 14.7% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 247 shares in the last quarter. Cambridge Advisors Inc. bought a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at about $202,000. Advisor Partners LLC bought a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at about $208,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at about $217,000. Hedge funds and other institutional investors own 97.27% of the company’s stock.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) opened at $117.75 on Monday. The company has a current ratio of 1.74, a quick ratio of 1.49 and a debt-to-equity ratio of 1.16. The company has a market capitalization of $5,604.17, a P/E ratio of 23.69, a PEG ratio of 1.89 and a beta of 0.94.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The business had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. During the same quarter in the previous year, the firm posted $1.20 earnings per share. Charles River Laboratories International’s quarterly revenue was up 8.1% on a year-over-year basis. equities analysts anticipate that Charles River Laboratories International, Inc. will post 5.1 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Crossmark Global Holdings Inc. Takes $2.57 Million Position in Charles River Laboratories International, Inc. (CRL)” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.com-unik.info/2017/11/06/crossmark-global-holdings-inc-takes-2-57-million-position-in-charles-river-laboratories-international-inc-crl.html.

CRL has been the topic of a number of research reports. Zacks Investment Research lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Robert W. Baird reaffirmed a “buy” rating and set a $114.00 target price on shares of Charles River Laboratories International in a research note on Friday, September 1st. Credit Suisse Group reaffirmed a “neutral” rating and set a $112.00 target price (up previously from $95.00) on shares of Charles River Laboratories International in a research note on Monday, October 16th. BidaskClub lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Barclays PLC reaffirmed a “hold” rating and set a $102.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 19th. Five equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $103.77.

In other news, insider Davide Molho sold 6,165 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $110.00, for a total value of $678,150.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David Ross Smith sold 2,552 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $67.10, for a total transaction of $171,239.20. Following the completion of the transaction, the insider now owns 11,671 shares in the company, valued at approximately $783,124.10. The disclosure for this sale can be found here. Insiders have sold 18,699 shares of company stock worth $1,892,393 in the last three months. 2.20% of the stock is currently owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

What are top analysts saying about Charles River Laboratories International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Charles River Laboratories International Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit